A prospective phase II clinical study of TACE combined with triplezumab and metronochemotherapy in the treatment of advanced hepatocellular carcinoma (HCC)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031692

Enrollment

Unknown

Registered

2020-04-07

Start date

2020-05-01

Completion date

Unknown

Last updated

2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma (HCC)

Interventions

Experimental group: TACE combined with triplezumab and metronochemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Ages 18-75 years; 2. Patients with advanced primary liver cancer who had failed first-line sorafenib treatment; 3. Estimated survival time >= 3 months; 4. The proportion of tumor in the whole liver was < 70%;Hepatocellular carcinoma in which the main portal vein is not completely obstructed, or in which the compensatory collateral vessels of the portal vein are abundant although the portal vein is completely obstructed, or in which portal vein blood flow can be reconnected by portal vein stent placement.

Exclusion criteria

Exclusion criteria: 1. Severe disorders of liver function, including severe jaundice, hepatic encephalopathy, refractory ascites or hepatorenal syndrome; 2. ECOG score of > 2, malignant fluid or multiple organ failure; 3. Patients with brain metastases; 4. History of autoimmune disease; 5. Hypersensitivity to intravenous contrast agents.

Design outcomes

Primary

Measure	Time frame
Total survival time;	—

Countries

China

Contacts

Public ContactWang Bo

The Seventh Affiliated Hospital of Sun Yat-Sen University

wangb68377@sina.com+86 15626154498

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026